Industry litigation – Page 5
-
OpinionThe price of failure
Drug market structures and high R&D failure rates can tempt companies into bad pricing behaviour
-
BusinessBudget cuts at UK medicines regulator raise eyebrows
MHRA to cut 300 jobs amid financial pressures arising from Brexit
-
BusinessDeveloping countries sidelined in Covid-19 vaccine scramble
Lack of funds and local manufacturing capacity has prevented Covax from competing with wealthier nations’ self-interest
-
BusinessIndustry tightens emissions reduction targets
As COP26 approaches, many firms are announcing ambitious climate goals. But are they achievable?
-
BusinessUS judge rules against GSK in trade secrets dispute
Firm will not receive compensation for claimed loses of over $1bn from theft of confidential information by two former scientists
-
BusinessUS supreme court will not hear J&J talc appeal
Decision means J&J must pay $2.1 billion previously awarded to 22 women who say talc caused their ovarian cancer
-
BusinessUS supreme court ends Sandoz–Amgen biosimilar dispute
Sandoz’s copy of arthritis drug Enbrel won’t be available in the US until 2029, 30 years after it was first marketed
-
BusinessWhat might UK Reach look like?
As the UK’s legal system finds its feet post-Brexit, stakeholders have mixed feelings about the changes it could bring
-
BusinessCoca-Cola chemist convicted of trade secret theft
Xiaorong You stole files detailing BPA-free can coatings from seven major chemicals firms
-
OpinionA powerful blow against misconduct
Supporting whistleblowers is vital for detecting and preventing bad behaviour
-
OpinionRewards based on priority drive unnecessary competition
The story of Crispr illustrates how a focus on patents and publications can cause good people to act in unsavoury ways
-
BusinessPatent applications listing AI as an inventor run into legal problems
Artificial intelligence is increasingly being used to find new chemical compounds and repurpose drugs, but should laws be updated to protect the intellectual property of such discoveries?
-
BusinessDuPont and spinoffs reach $4bn settlement to resolve PFAS liability issues
DuPont, Chemours and Corteva have also reached an $83mn agreement to settle 95 pending personal injury cases in Ohio related to PFAS
-
BusinessBrexit may put some chemicals out of GB’s Reach
Industry fears divergence of UK and EU regulations could spell disaster for trade
-
BusinessCovid-19 highlights need to update pharma supply chains
Resilience and redundancy are key amid protectionist calls for domestic manufacturing
-
BusinessArkema acquitted over hurricane fire emissions
US Judge rules there is insufficient evidence to bring criminal charges relating to peroxide fire caused by flooding in 2017
-
OpinionFrom collaboration to collusion
The US government’s crackdown on academics not declaring Chinese funding highlights a moral hazard
-
BusinessDeadly Indian incidents highlight relaxed regulations
Concern over human and environmental cost of reforms aimed at ease of doing business
-
BusinessAppeals court cuts damages further in glyphosate cancer case
Judgment retains verdict that Bayer-Monsanto’s herbicide caused US man’s cancer
-
BusinessBayer commits over $10bn to resolve legacy Monsanto lawsuits
Agreement settles about 75% of Roundup-related cases and resolves PCB and dicamba litigation